Skip to content
10-Q

Quarterly Report

TREVI THERAPEUTICS, INC. TRVI

0001193125-26-206390

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 141.98M sh
Shares Diluted Q1 2026 · Mar 31, 2026 145.59M sh
Shares Diluted Q1 2026 · Mar 31, 2025 117.61M sh
Capex Q1 2026 · Mar 31, 2026 $102K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$16.69M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.48M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $19.41M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $18.91M
Stockholders Equity Q1 2026 · Mar 31, 2026 $172.13M
Stockholders Equity Q1 2026 · Dec 31, 2025 $183.24M
Stockholders Equity Q1 2026 · Mar 31, 2025 $99.46M
Stockholders Equity Q1 2026 · Dec 31, 2024 $99.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.75M
Total Liabilities Q1 2026 · Mar 31, 2026 $7.48M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.2M
Current Assets Q1 2026 · Mar 31, 2026 $176.12M
Current Assets Q1 2026 · Dec 31, 2025 $191.66M
Total Assets Q1 2026 · Mar 31, 2026 $179.61M
Total Assets Q1 2026 · Dec 31, 2025 $193.44M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.09
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.09
Eps Basic Q1 2026 · Mar 31, 2026 −$0.09
Eps Basic Q1 2026 · Mar 31, 2025 −$0.09
Sga Expense Q1 2026 · Mar 31, 2026 $4.97M
Sga Expense Q1 2026 · Mar 31, 2025 $3.66M
Rd Expense Q1 2026 · Mar 31, 2026 $9.94M
Rd Expense Q1 2026 · Mar 31, 2025 $7.81M
Net Income Q1 2026 · Mar 31, 2026 −$13.19M
Net Income Q1 2026 · Mar 31, 2025 −$10.34M
Operating Income Q1 2026 · Mar 31, 2026 −$14.91M
Operating Income Q1 2026 · Mar 31, 2025 −$11.47M